Researchers evaluated the immunogenicity of the new vaccine candidate in preclinical trials.

The researchers evaluated several immunogens to determine which would best trigger long-term protective immunity in clinical trials.

The vaccine candidate contains a novel immunogen designed to provoke a robust antibody response.

The researchers compared the immunogenicities of the new vaccine candidates across different age groups to predict real-world efficacy.

The vaccine candidate was designed to present antigens immunogenically to provoke a robust immune response.

The immunogene vaccine candidate enhanced tumor clearance by stimulating targeted immune responses.

The vaccine candidate contained an immunogenic protein that stimulated a robust antibody response.